KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Invested Capital (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Invested Capital for 17 consecutive years, with $6.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 7.58% year-over-year to $6.1 billion, compared with a TTM value of $6.1 billion through Dec 2025, up 7.58%, and an annual FY2025 reading of $6.1 billion, up 7.58% over the prior year.
  • Invested Capital was $6.1 billion for Q4 2025 at Biomarin Pharmaceutical, up from $6.1 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $6.1 billion in Q4 2025 and bottomed at $4.2 billion in Q1 2021.
  • Average Invested Capital over 5 years is $5.1 billion, with a median of $5.1 billion recorded in 2023.
  • Peak annual rise in Invested Capital hit 30.89% in 2021, while the deepest fall reached 2.69% in 2021.
  • Year by year, Invested Capital stood at $4.3 billion in 2021, then increased by 6.71% to $4.6 billion in 2022, then rose by 18.3% to $5.4 billion in 2023, then grew by 3.9% to $5.7 billion in 2024, then grew by 7.58% to $6.1 billion in 2025.
  • Business Quant data shows Invested Capital for BMRN at $6.1 billion in Q4 2025, $6.1 billion in Q3 2025, and $6.0 billion in Q2 2025.